Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nasdaq
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(500)
•••
Comment by crow27on Feb 13, 2021 3:13pm
199 Views
Post# 32562484

RE:RE:RE:RE:RE:Nasdaq

RE:RE:RE:RE:RE:NasdaqSo True 3burtc, one almosts forgets the other products that ATE has. This Nuance deal was only for otenaproxesu and that was only aprox 10% of the worldwide pharma market.
100 million PLUS royalties for 10% ..................... sweet!! 
ATB could blow this bio market wide open with just otenaproxesu never mind their other products. 
This deal will and has got the attention of all pharma companies and if they have a brain in their head they will also make some sort of deal with ATE.
I would not want to be the guy that works for big pharma and does not bring this to their attention.
In very short order you will be handed your a ss as they walk you out the door.
Next week should be a blast!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities